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Abstract. Yemen is a country that has been treating severe cases of oncho-dermatitis since 1992 and is nowmoving
to a program aimed at the elimination of the transmission of Onchocerca volvulus. It is important to ensure that the
currently acceptable tools used in epidemiological assessment of onchocerciasis inAfrica andLatinAmerica alsoapply to
Yemen. Fivehundredand tenblood samples from three knownO. volvulus–endemic areas, locations that havenever been
under a mass treatment program, were tested for the presence of antibodies against a panel of O. volvulus–speciﬁc
antigens using enzyme-linked immunosorbent assay (Ov16) and luciferase immunoprecipitation system (OvFAR-1 and
Ov-MSA1) assays. Overall, 31.4% of the samples tested were positive, with positivity increasing with age. Positivity was
seen in 76.5% of those presenting with clinical onchocerciasis but importantly also in more than 28.5% of those deﬁned
as free of oncho-dermatitis; these latter individuals are likely to be serving as a source for persistent reinfection. This study
supports the use of the current O. volvulus–speciﬁc serologic methodology in Yemen.
Onchocerciasis in Yemen was ﬁrst recognized through
its association with the characteristic dermatological pre-
sentation of onchocerciasis characterized by increased
hyperpigmentation of the skin in localized areas of the
body; indeed, this form of the disease has acquired a local
Yemeni name “sowdah,” the Arabic word for “dark.”1 Based
on the predominance of this condition in the local endemic
populations, a clinical treatment program was setup to
treat those suffering from this reactive form of oncho-
dermatitis.2–4 To move the national onchocerciasis pro-
gram from a disease control to an elimination program
for the approximately 300,000 people likely to be ex-
posed to this infection,3 in keeping with the current global
approach,5,6 there is a need to ensure that the standard
epidemiological indicator currently used in onchocerciasis
programs (onchocerciasis serology) is applicable to Yemen.
In addition, there is a need for epidemiological evidence to
support a move from a successful treatment-oriented
program to a mass drug program (MDA). Blood samples
were collected from residents of Yemeni onchocerciasis
areas in three governorates in the mountain range run-
ning parallel to the Red Sea (Figure 1) and tested for
onchocerciasis.
Five hundred and ten residents were selected (298 males
and 212 females) from three MDA-free wadis within the area
known to be endemic for “sowdah,” namely, Wadi Al Zabid,
Wadi Al Ana, and Wadi Al Ghail (Figure 1). Selection of indi-
viduals living in these riverside villages was carried out on a
random basis, ensuring to include those who were suffering,
or had suffered, from “sowdah” and their family members.
Participants were questioned about their personal histories
relating to oncho-dermatitis (i.e., sowdah). Hundred and
twenty-three people who had “sowdah” or had been under
treatment of this condition were included, and an additional
387 individuals were, and had always been, free of clinical
onchocerciasis butwere exposed to the infection as theywere
living in endemic area also included. None of those people
sampled carried onchocercal nodules, which is typical for
Yemeni onchocerciasis.3,4 Blood samples, collected by ﬁnger
prick extraction, were collected on Whatman ﬁlter paper,
dried, and dry-stored at −20C for processing in the labora-
tory. The blood samples were extracted by standardmethods
and processed for the presence of onchocercal antibodies.
IgG4 antibodies to Ov16 were determined by a standardized
FIGURE 1. The location of the study, the three endemic sites in the
Yemeni onchocerciasis area (the known endemic area indicated by
the area ringed along themountainousRedSeaborder of the country).
(A) Wadi Al Zabid, (B) Wadi Al Ana, and (C) Wadi al Ghail.
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enzyme-linked immunosorbent assay (ELISA) performed ex-
actly as previously described.7 Cutoffs for positivity were
based on ROC analyses. True positives were serum from skin
snip positive (mf+) individuals from the Americas (Ecuador,
Guatemala), aswell asWest (Ghana), Central (Cameroon), and
East Africa (Uganda). True negatives were healthy North
American donors who had traveled outside of North America.
The assay was set for 99–100% speciﬁcity and the sensitivity
was 80%. The skin snip biopsy technique for microﬁlarial as-
sessmentwasnot used in this study as it is currently not part of
the national program protocol; indeed, “sowdah” patients are
as a rule negative in this “live parasite” assay as they are ac-
tively killing the microﬁlariae in their dermal tissues.
The luciferase immunoprecipitation system (LIPS) assays to
detect IgG antibodies to OvFAR-1 and Ov-MSA1 antigens
were performed as described previously,8 except that an input
TABLE 1
The relationship of Onchocerca volvulus seropositivity to the clinical presentation of onchocerciasis in 498 residents
Clinical presentation
Al Ghail Al Ana Al Zabid Total
Ov+ Ov− Ov+ Ov− Ov+ Ov− Ov+ Ov−
Presenting with oncho-dermatitis 3 1 5 6 18 1 26* (76.5%) 8
Presenting only with increased pruritus 5 15 0 0 4 2 9 (34.6%) 17
Free of either oncho-dermatitis or
increased pruritus
46 136 34 105 45 72 125 (28.5%) 313
The clinical status of 12 patients in the blood survey was not recorded. Number (% of individuals in respective clinical subgroup).
* All of these were Ov antibody positive in both serological tests (see Table 3).
FIGURE 2. The differences in Onchocerca volvulus positivity between males and females resident in the three different endemic zones of
onchocerciasis in Yemen.
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of 1 million luminometer units (LU) of the enzyme reporter
Ruc-OvFAR-1 and 300,000 LU of the Ruc-Ov-MSA1 was
used. Brieﬂy, 1 μL of patient serumwas diluted 1τ10 in assay
buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM, 1% Triton
x-100). The plate was incubated for 5 minutes at room tem-
perature after which 7 μL of a 30%suspension of protein A/G
beads in PBS (Pierce Biotechnology, Rockford, IL) was
added to the mixture in a 96-well ﬁlter HTS plate (Millipore,
Bedford, MA). After 5 minutes, the ﬁlter plate containing the
mixture was applied to a vacuummanifold andwashed twice
in assay buffer and eight times with PBS. After the ﬁnal wash,
all plates were processed on a Berthold LB 960 Centro
microplate luminometer using a colenterazine substrate mix
(Promega, Madison, WI). All data were the average of tripli-
cates corrected for background reactivity (no serum added).
The cutoffs for positivity used were based on ROC analyses
as described previously.8
Hundred and sixty individuals, 31.4% of those tested of
all those sampled, were positive to one or more of the three
antigens tested, and the proﬁle of this positive group in-
cluded both individuals who had a history of oncho-
dermatitis (76.5% of this clinical subgroup) and those
with no history of the clinical disease (28.5% of this sub-
group) (Table 1). A third (34.6%) of those who presented
with increased pruritus, although not showing any other
signs or symptoms of oncho-dermatitis, were positive for
Onchocerca volvulus–speciﬁc antibodies. Both males and
females were positive in this testing (Figure 2), with the
prevalence of positivity increasing with age (Table 2). There
were differences in age-speciﬁc prevalence that are not
consistent between age groups; this may relate to differ-
ences in time of exposure to infected ﬂies between males
and females of different ages. In this society, young women
tend to spend more time at the riverside (e.g., washing
clothes) than older women (who tend to remain in the
houses) do; in addition, men (c.f. women) often travel away
from the endemic area. The testing of a larger number of
people is probably needed to ensure that these differences
are valid.
These results indicate ﬁrst that anti-O. volvulus anti-
bodies are present in residents of the onchocerciasis-
endemic areas of Yemen, including antibodies directed at
Ov16, the antigen target used as the global program epi-
demiological indicator.6 The use of a panel of three different
antigens (Ov16, OvFAR-1, and Ov-MSA1) has increased
the sensitivity of the study above that if only using Ov16
(Table 3), which arguably has a sensitivity of no greater than
80%. Since its discovery in 1989, the sensitivity of Ov16
has rarely been greater than 80% in immunoassays when
the speciﬁcity was tuned for > 99% against mf + Ov-
infected patients. This ﬁnding is known to be related toMHC
class II haplotypes, as the response to Ov16 is DR-
restricted. Luciferase immunoprecipitation system con-
structs for Ov16 have only been recently developed and in
this present study. Enzyme-linked immunosorbent assays
were used in this present study as usable LIPS constructs
for Ov16 have only recently been developed. In general, the
sensitivity of LIPS for Ov16 antibodies has not been sig-
niﬁcantly different from that for ELISAs or for the commer-
cially available RDT.
The substantial number of positive individuals free of any
history of clinical disease, and thus not previously included
in the established clinical program, are likely to have been
a major source of continuing reinfection to the focus
and need to be included in an MDA if elimination is to be
achieved.
This study shows that the currently approved epidemio-
logical procedures recommended in the World Health
Organization elimination guidelines that involve measuring
onchocercal antibodies can be applied for the elimination in
Yemen.9
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TABLE 2
Total numbers of residents studied in each endemic area and
their seropositivity for Onchocerca volvulus—number studied (%
positivity)
Group Wadi Al Ghail Wadi Al Ana Wadi Al Zabid Total population
All residents 210 (26.2%) 151 (25.2%) 149 (45.0%) 510 (31.4%)
Males 136 (36.0%) 88 (30.7%) 74 (67.6%) 298 (42.3%)
Females 74 (9.5%) 63 (20.6%) 75 (29.3%) 212 (19.8%)
Ages 12–19
years
74 (4.1%) 54 (14.8%) 34 (26.5%) 162 (12.4%)
Ages 20–39
years
49 (36.7%) 50 (42.0%) 45 (55.6%) 144 (44.4%)
Ages > 39
years
87 (49.4%) 47 (46.8%) 70 (74.29%) 204 (75.4%)
TABLE 3
Positivity to the different antibody assays: ELISA for Ov16 and LIPS for OvFAR1/Ov-MSA1
Group
Number positive in
OV16 (ELISA) only
Number positive in
OvFAR1/Ov-MSA1 LIPS
Number positive for
both OV16 and OvFAR1/Ov-MSA1 Positive in any test N (%) Number negative in all tests N (%)
Wadi Al Ana N = 151 2 23 13 38 (25.2%) 113 (74.8%)
Wadi Al Zabid N = 149 2 51 14 67 (45.0%) 82 (55.0%)
Wadi Al Ghail N = 210 4 30 21 55 (26.2%) 155 (73.8%)
Totals 8 104 48 160 (31.4%) 350 (68.6%)
ELISA = enzyme-linked immunosorbent assay; LIPS = luciferase immunoprecipitation system.
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